Search Results (2)

Background: Obesity impairs renal function through direct mechanisms, such as proinflammatory adipocytokine production, and indirect mechanisms, including obesity-related comorbidities. Despite the increasing prevalence of obesity and chronic kidney disease (CKD), clinical guidelines for their combined management remain lacking. Very Low Energy Ketogenic Therapy (VLEKT) has demonstrated efficacy in weight loss, but evidence on its safety and efficacy in individuals with obesity and mild renal impairment is limited. This study aimed to assess the efficacy and safety of Phase 1 of VLEKT in individuals with obesity and mild renal impairment. Methods: This cross-sectional study included 73 individuals with overweight or obesity (mean age 53.7 ± 8.8 years; BMI 35.3 ± 4.2 kg/m²) and an estimated glomerular filtration rate (eGFR) of at least 60 mL/min/1.73 m² (evaluated using the CKD-EPI equation). Anthropometric (weight, BMI, and waist circumference) and biochemical parameters (fasting plasma glucose, insulin, cholesterol profile, triglycerides, AST, ALT, and urea) were collected at baseline and after 45 (±2) days of Phase 1 of VLEKT. Results: At baseline, 54.8% of participants had an eGFR <90 mL/min/1.73 m², while 45.2% had an eGFR ≥ 90 mL/min/1.73 m², with no significant differences in sex distribution. After 45 (±2) days of Phase 1 of VLEKT, both groups showed significant reductions in BMI (p < 0.001), waist circumference (p < 0.001), fasting plasma glucose (p ≤ 0.004), insulin (p < 0.001), HOMA-IR (p < 0.001), total cholesterol (p < 0.001), LDL cholesterol (p < 0.001), LDL/HDL ratio (p ≤ 0.002), triglycerides (p ≤ 0.009), AST (p ≤ 0.034), and ALT (p ≤ 0.009). Notably, the eGFR significantly increased in participants with an eGFR < 90 mL/min/1.73 m² (p < 0.001), while no changes were observed in those with an eGFR ≥ 90 mL/min/1.73 m². Conclusions: Phase 1 of VLEKT could effectively promote weight loss and metabolic improvements without compromising renal function, even in individuals with obesity and mild renal impairment. Further research is warranted to confirm the efficacy and safety of VLEKT and to assess outcomes across all protocol phases. Full article

Background: Obesity is constantly growing worldwide, representing a serious concern also for healthcare costs. Current anti-obesity pharmacological strategies, although effective, represent a significant cost for the patient. Similarly, very low energy ketogenic therapy (VLEKT) protocols with replacement meals also have high costs. Objectives: The objective of this study was to estimate the average costs of a VLEKT protocol with replacement meals compared with those of isocaloric diets with fresh foods. Methods: VLEKTs with replacement meals and fresh foods were developed considering an ideal young woman and man with grade II obesity (BMI ≥ 35.0 kg/m²). The costs of the individual fresh foods were extrapolated from official Italian databases. The costs of replacement meals were obtained by consulting the catalogs of three companies specialized in VLEKTs operating in Italy. Results: On a monthly basis, VLEKT with fresh food had an average cost of EUR 253.44 and EUR 295.67, while VLEKT with replacement meals had an average cost of EUR 434.91 and EUR 535.99, for the woman and man, respectively. Conclusions: Although more expensive than a common diet, VLEKT should be seen not only as a dietary method for losing weight, but as a non-pharmacological, medicalized nutritional therapy, useful for managing various conditions, even those not directly related to obesity. Like a drug therapy, VLEKT requires the use of specific products that entail a higher cost, to be borne by the patient, but whose benefits should be emphasized, which go beyond weight loss and concern general health, thus considering them as a targeted nutritional strategy. Full article